Medicenna Therapeutics announced the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee, DAC, a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy. Dr. Arash Yavari is a University Research Lecturer and Principal Investigator at the Radcliffe Department of Medicine, University of Oxford, CSO of Imbria Pharmaceuticals, and serves as Senior Drug Development Clinician with Weatherden.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
- Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
- Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
- Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
- Medicenna reports U.S. patent granted for use of Interleukin-2 Superkine protein